Warning
Major Pharmaceuticals Recalls Levothyroxine Sodium Tablets
This is a Class II recall. This product may cause temporary health problems or pose a slight threat of a serious nature.
Source: FDA
WarningRecall #D-0706-2026Drug / Pharmaceutical
Major Pharmaceuticals Recalls Levothyroxine Sodium Tablets
Major Pharmaceuticals · Class II — Moderate Risk
Product Description
Levothyroxine Sodium Tablets, USP, 150 mcg (0.0150 mg), 100 Tablets (10 x 10 unit dose blisters) per carton, Rx only, Packaged and Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN 46268 USA. NDC: 0904-6956-61
Reason for Recall
Subpotent Drug
FDA Classification
Class II — Moderate Risk
A situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
Distribution
Nationwide in the USA.
Remedy
Consumers should stop using this product. Contact the recalling firm for further instructions regarding this product.
411 Press Analysis
The FDA classified this recall as Class II, indicating the pharmaceutical product may cause temporary health problems or poses a slight threat of a serious nature. Major Pharmaceuticals initiated the recall on July 13, 2026. Subpotent Drug. The product was distributed nationwide. Consumers should check their purchases and discontinue use of any affected product. Contact Major Pharmaceuticals for further instructions.
Sources: FDA openFDA Enforcement Database
This recall appears in: Drug & Medication Defects.